A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with aggressive disease.

“Early decline in prostate-specific antigen (PSA) to very low levels is one of the strongest predictors of long-term survival in metastatic prostate cancer. However, clinicians currently have to wait up to six months after starting therapy to see whether a patient achieves this favorable response. For patients who do not respond well, this delay may allow the cancer to progress and become more resistant to treatment,” said Soumyajit Roy, MD, a radiation oncologist at UH Seidman Cancer Center and first author of the study.

Because existin...

Due to our ever-increasing reliance on electronics, researchers are always on the lookout for battery materials with more desirable qualities. Common battery materials, like lithium, can be prone to disadvantages like overheating and material sourcing issues, leading to safety risks and higher costs.

Now, researchers from China have revealed a new battery design that may offer a better alternative to lithium...

Researchers at Leipzig University and the University of Gothenburg have developed a novel approach to assessing an individual’s risk of metabolic diseases such as diabetes or fatty liver disease more precisely. Instead of relying solely on the widely used body mass index (BMI), the team developed an AI-based computational model using metabolic measurements. This so-called metabolic BMI shows that people of normal weight with a high metabolic BMI have up to a fivefold higher risk of metabolic disease. The findings have been published in the journal Nature Medicine.

The conventional body mass index, calculated using height and weight, may indicate overweight but does not reflect how healthy or unhealthy body fat actually is...